Harvard University Licenses DiscoveryGate® Content Platform

Harvard University Licenses DiscoveryGate® Content Platform

San Ramon, CA – October 25, 2006 – Elsevier MDL is pleased to announce that Harvard University has licensed the DiscoveryGate® content platform. The same premier, structure-searchable resource for scientific information that is used by life sciences research organizations industry-wide is now available to students, faculty and researchers at one of the world’s pre-eminent academic institutions.

“To maintain its competitive advantage in life sciences research, Harvard must offer the entire university simplified access to the information required to answer discovery questions,” said Marcia Chapin, head librarian for the Chemistry & Chemical Biology Library. “By providing straightforward access to richly-excerpted content, DiscoveryGate will enable researchers at Harvard to spend more time productively exploring critical information that furthers their research interests.”

“In selecting DiscoveryGate, a content platform well suited for navigating today’s rapidly changing life sciences landscape, Harvard University is leading the way for other institutions of higher learning,” said Elsevier MDL President and CEO Lars Barfod. “Harvard has provided valuable feedback on DiscoveryGate beginning with our initial customer validation program in 2003, and this has helped immensely in making DiscoveryGate the unparalleled source of discovery data that it is today.”

DiscoveryGate’s unique integration and linking of content enables researchers to compare information and results that are not available through other systems. The platform provides access to more than 20 million chemical compounds, 11 million reactions and 500 million observed chemical facts, including synthesis, bioactivity, metabolism, toxicology, physical property, chemical sourcing, pharmacology and patent data—all from a single query.

Using DiscoveryGate, researchers can access 17 databases including the Beilstein and Gmelin databases (which are also available on the Crossfire system from MDL Information Systems GmbH), MDL® Available Chemicals Directory, MDL® Drug Data Report, MDL® Toxicity and authoritative reference works on synthetic methodology. Researchers can also search compounds in third-party databases such as PubChem and the Derwent World Patents Index®, and they can link to over 20,000 journal titles (with additional licenses required to access certain third-party content).

To learn more about how DiscoveryGate helps academic researchers find the information they need, visit gateway.discoverygate.com, contact your Elsevier MDL Account Manager or request information at www.mdl.com.

###

About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services.

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Jean Holt
Tel: +1 (925) 543-5400
E-mail: j.holt@mdl.com